Ischemic Stroke, Precerebral Occlusion DRG 061 Reimbursement

Acute thrombolysis optimization studies: Trials focusing on refining administration protocols, timing windows, and adjunctive measures for thrombolytic therapy in patients presenting with acute ischemic stroke or transient ischemic attacks who receive systemic thrombolytics. These studies typically enroll patients within the early emergency department or stroke unit window and investigate outcomes such as reperfusion rates, symptomatic hemorrhage, and early neurological improvement. Findings inform emergency stroke pathways and resource utilization decisions that directly affect hospital length of stay and costs for this DRG.
Comparative effectiveness and safety studies of reperfusion strategies: Research comparing systemic thrombolysis alone versus combinations with endovascular approaches or differing anticoagulation/antiplatelet strategies in subgroups such as large-vessel occlusion, precerebral stenosis, or patients with significant comorbidities (for example, atrial fibrillation or prior anticoagulant use). These studies address which patient populations derive the greatest net benefit and the trade-offs in complication rates and secondary interventions, providing evidence useful for clinical protocols, case-mix adjustment, and payer coverage decisions.
Post-acute outcomes, rehabilitation, and readmission prevention research: Trials and observational studies evaluating inpatient rehabilitation timing, intensity, secondary prevention adherence, and care transitions for patients who received thrombolytic therapy with major complications or comorbidities (MCC). These investigations measure functional recovery, discharge disposition (home versus skilled nursing facility), 30- and 90-day readmission rates, and cost-effectiveness of post-discharge services. Results are relevant for hospitals and payers aiming to reduce avoidable readmissions, optimize post-acute placement, and align reimbursement with expected outcomes for this high-acuity DRG.

Acute thrombolysis optimization studies: Trials focusing on refining administration protocols, timing windows, and adjunctive measures for thrombolytic therapy in patients presenting with acute ischemic stroke or transient ischemic attacks who receive systemic thrombolytics. These studies typically enroll patients within the early emergency department or stroke unit window and investigate outcomes such as reperfusion rates, symptomatic hemorrhage, and early neurological improvement. Findings inform emergency stroke pathways and resource utilization decisions that directly affect hospital length of stay and costs for this DRG.
Comparative effectiveness and safety studies of reperfusion strategies: Research comparing systemic thrombolysis alone versus combinations with endovascular approaches or differing anticoagulation/antiplatelet strategies in subgroups such as large-vessel occlusion, precerebral stenosis, or patients with significant comorbidities (for example, atrial fibrillation or prior anticoagulant use). These studies address which patient populations derive the greatest net benefit and the trade-offs in complication rates and secondary interventions, providing evidence useful for clinical protocols, case-mix adjustment, and payer coverage decisions.
Post-acute outcomes, rehabilitation, and readmission prevention research: Trials and observational studies evaluating inpatient rehabilitation timing, intensity, secondary prevention adherence, and care transitions for patients who received thrombolytic therapy with major complications or comorbidities (MCC). These investigations measure functional recovery, discharge disposition (home versus skilled nursing facility), 30- and 90-day readmission rates, and cost-effectiveness of post-discharge services. Results are relevant for hospitals and payers aiming to reduce avoidable readmissions, optimize post-acute placement, and align reimbursement with expected outcomes for this high-acuity DRG.

OpenPayer

Summary & Overview

Ischemic Stroke with Thrombolytic Agent and MCC: Inpatient Reimbursement Overview

DRG 061 Overview

Clinical Trials

Related Codes

Clinical Trials

Related Codes